publication date: Dec. 6, 2013Wall Street Analyst Who Sounded Alarm Over Prostate Cancer Drug Provenge In JNCI Settles with SEC Over Shorting Dendreon Stock An Earmark in the Making: NCI Urged to Boost Gastric Cancer Funding Johnson to Leave NCI Office of Communications FDA Expands Nexavar Indication to Include Thyroid Cancer
Download the PDF
Documents referenced in this issue of The Cancer Letter can be found here
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.